<DOC>
	<DOCNO>NCT00116688</DOCNO>
	<brief_summary>The purpose study determine safety romiplostim long-term treatment thrombocytopenic subject ITP , evaluate long-term platelet response romiplostim , evaluate change patient report outcome due use romiplostim . Participants must previously complete romiplostim ITP study .</brief_summary>
	<brief_title>Open Label Extension Study Romiplostim ( AMG 531 ) Thrombocytopenic Patients With Immune ( Idiopathic ) Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Must previously complete romiplostim ITP study Platelet count â‰¤ 50 x 10 ^9/L Written inform consent Bone marrow stem cell disorder new active malignancy diagnose since enrollment previous romiplostim ITP study Received alkylating agent within 4 week screen visit anticipate use time propose study Currently enrol yet complete least 4 week since end device drug trial ( ) ( previous romiplostim ITP study ) , subject receive investigational agent ( ) romiplostim Not use adequate contraceptive precaution Not available followup assessment Has kind disorder compromise ability participant give inform consent legallyacceptable representative and/or unable comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Immune ( Idiopathic ) Thrombocytopenic Purpura ( ITP )</keyword>
	<keyword>Thrombocytopenic</keyword>
</DOC>